Literature DB >> 19389584

Depression and immunity: inflammation and depressive symptoms in multiple sclerosis.

Stefan M Gold1, Michael R Irwin.   

Abstract

An increasing body of evidence suggests that patients who have major depressive disorder show alterations in immunologic markers including increases in proinflammatory cytokine activity and inflammation. Inflammation of the central nervous system is a pathologic hallmark of multiple sclerosis (MS). Patients affected by this disease also show a high incidence of depression. Accumulating evidence from animal studies suggests that some aspects of depression and fatigue in MS may be linked to inflammatory markers. This article reviews the current knowledge in the field and illustrates how the sickness behavior model may be applied to investigate depressive symptoms in inflammatory neurologic diseases.

Entities:  

Mesh:

Year:  2009        PMID: 19389584      PMCID: PMC3625861          DOI: 10.1016/j.iac.2009.02.008

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  83 in total

1.  Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample.

Authors:  Lydia Chwastiak; Dawn M Ehde; Laura E Gibbons; Mark Sullivan; James D Bowen; George H Kraft
Journal:  Am J Psychiatry       Date:  2002-11       Impact factor: 18.112

2.  Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity.

Authors:  Florian Kaestner; Michael Hettich; Marion Peters; Walter Sibrowski; Günter Hetzel; Gerald Ponath; Volker Arolt; Uwe Cassens; Matthias Rothermundt
Journal:  J Affect Disord       Date:  2005-08       Impact factor: 4.839

3.  Lesions in the left arcuate fasciculus region and depressive symptoms in multiple sclerosis.

Authors:  J Pujol; J Bello; J Deus; J L Martí-Vilalta; A Capdevila
Journal:  Neurology       Date:  1997-10       Impact factor: 9.910

Review 4.  A systematic review of the mortality of depression.

Authors:  L R Wulsin; G E Vaillant; V E Wells
Journal:  Psychosom Med       Date:  1999 Jan-Feb       Impact factor: 4.312

5.  The role of helplessness as mediator between neurological disability, emotional instability, experienced fatigue and depression in patients with multiple sclerosis.

Authors:  S P van der Werf; A Evers; P J H Jongen; G Bleijenberg
Journal:  Mult Scler       Date:  2003-02       Impact factor: 6.312

6.  An examination of suicidal intent in patients with multiple sclerosis.

Authors:  Anthony Feinstein
Journal:  Neurology       Date:  2002-09-10       Impact factor: 9.910

7.  Cytokine mRNA expression in patients with multiple sclerosis and fatigue.

Authors:  Peter Flachenecker; Irene Bihler; F Weber; M Gottschalk; Klaus V Toyka; Peter Rieckmann
Journal:  Mult Scler       Date:  2004-04       Impact factor: 6.312

8.  Psychosocial correlates of fatigue in multiple sclerosis.

Authors:  C E Schwartz; L Coulthard-Morris; Q Zeng
Journal:  Arch Phys Med Rehabil       Date:  1996-02       Impact factor: 3.966

9.  Structural brain abnormalities in multiple sclerosis patients with major depression.

Authors:  A Feinstein; P Roy; N Lobaugh; K Feinstein; P O'Connor; S Black
Journal:  Neurology       Date:  2004-02-24       Impact factor: 9.910

10.  Fatigue is not associated with raised inflammatory markers in multiple sclerosis.

Authors:  G Giovannoni; A J Thompson; D H Miller; E J Thompson
Journal:  Neurology       Date:  2001-08-28       Impact factor: 9.910

View more
  30 in total

Review 1.  Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions.

Authors:  Kristen Farrell; Michael H Antoni
Journal:  Fertil Steril       Date:  2010-05-14       Impact factor: 7.329

2.  Smaller cornu ammonis 2-3/dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms.

Authors:  Stefan M Gold; Kyle C Kern; Mary-Frances O'Connor; Michael J Montag; Aileen Kim; Ye S Yoo; Barbara S Giesser; Nancy L Sicotte
Journal:  Biol Psychiatry       Date:  2010-06-19       Impact factor: 13.382

3.  Symptoms and Functional Limitations in the First Year Following a Myocardial Infarction: A Qualitative Study.

Authors:  Chad Gwaltney; Matthew Reaney; Meaghan Krohe; Mona M Martin; Heather Falvey; Patrick Mollon
Journal:  Patient       Date:  2017-04       Impact factor: 3.883

Review 4.  Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies.

Authors:  Jennifer M Loftis; Marilyn Huckans; Benjamin J Morasco
Journal:  Neurobiol Dis       Date:  2009-11-26       Impact factor: 5.996

Review 5.  Low Vs. High Alcohol: Central Benefits Vs. Detriments.

Authors:  Yousef Tizabi; Bruk Getachew; Clifford L Ferguson; Antonei B Csoka; Karl M Thompson; Alejandra Gomez-Paz; Jana Ruda-Kucerova; Robert E Taylor
Journal:  Neurotox Res       Date:  2018-01-04       Impact factor: 3.911

6.  Animal models of depression: molecular perspectives.

Authors:  Vaishnav Krishnan; Eric J Nestler
Journal:  Curr Top Behav Neurosci       Date:  2011

7.  High frequency and intensity of drinking may attenuate increased inflammatory cytokine levels of major depression in alcohol-use disorders.

Authors:  Sudan P Neupane; Lars Lien; Priscilla Martinez; Pål Aukrust; Thor Ueland; Tom E Mollnes; Knut Hestad; Jørgen G Bramness
Journal:  CNS Neurosci Ther       Date:  2014-07-03       Impact factor: 5.243

8.  Unpredictable Chronic Mild Stress Paradigm Established Effects of Pro- and Anti-inflammatory Cytokine on Neurodegeneration-Linked Depressive States in Hamsters with Brain Endothelial Damages.

Authors:  Ennio Avolio; Gilda Fazzari; Maria Mele; Raffaella Alò; Merylin Zizza; Wei Jiao; Anna Di Vito; Tullio Barni; Maurizio Mandalà; Marcello Canonaco
Journal:  Mol Neurobiol       Date:  2016-10-11       Impact factor: 5.590

Review 9.  [Coexistent depressive and anxiety disorders in epilepsy and multiple sclerosis: a challenge to neuropsychiatric practice].

Authors:  Hans-Peter Kapfhammer
Journal:  Neuropsychiatr       Date:  2014-05-20

Review 10.  Duality of Antidepressants and Neuroprotectants.

Authors:  Yousef Tizabi
Journal:  Neurotox Res       Date:  2015-11-27       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.